Global Latent Tuberculosis Infection (LTBI) Testing Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Latent Tuberculosis Infection (LTBI) Testing Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Latent Tuberculosis Infection (LTBI) Testing market finds that the global Latent Tuberculosis Infection (LTBI) Testing market reached a value of USD 1241.01 million in 2022. It’s expected that the market will achieve USD 2188.48 million by 2028, exhibiting a CAGR of 9.92% during the forecast period.

Market Challenges

In most cases, TB is treatable and curable. However, standard TB treatment requires up to six months of drugs that can cause nausea, vomiting, and stomach pain. The duration and side effects drive some people to abandon their treatment, which can lead to drug resistance – when TB bacteria is resistant to at least one of the main TB drugs. In 2019, an estimated 500,000 people developed DR-TB and 182,000 died globally.

Drug-resistant TB is part of the growing challenge of antimicrobial-resistant superbugs that do not respond to existing medications, resulting in fewer treatment options and increasing mortality rates for illnesses that would ordinarily be curable – including TB. Multidrug-resistant TB now accounts for One-third of the world's deaths from antimicrobial resistance. Once it becomes drug-resistant tuberculosis, it will take longer to treat, and the treatment will be more difficult. The cost of treatment will be more than 10 times higher than that of general tuberculosis, and the cure rate will be lower. At the same time, once drug-resistant tuberculosis is transmitted to others, the infected person will also become drug-resistant tuberculosis.

With the increase of drug-resistant tuberculosis, the cost of disease management will increase, and people's demand for diagnosis and treatment may weaken, which will hinder the development of the Latent Tuberculosis Infection (LTBI) Testing market and challenge the Latent Tuberculosis Infection (LTBI) Testing market.

TST results are affected by a complex array of factors such as age, nutritional and immunological status, the time interval between antigen exposure and the test performance, BCG vaccination, immunosuppression, genetic background, and cross-reactivity with environmental non-tuberculosis mycobacteria and perhaps other pathogens. ELISPOT technique can quantify the number of IFN-γ-producing T cells (spot-forming cells). It requires expensive readers and software and specialized trained personnel, which restricts its clinical application in developing countries. The performance of the IGRA tests can be affected by several factors, mainly related to an impaired immune response and to technical issues. For example, the addition of IL-7 increases test positivity. The clinical accuracy of IGRAs seems to be negatively affected in patients with immune-mediated inflammatory diseases (IMIDs) such as Crohn's disease, where the function of immune cells is suppressed, as well as in patients on immun omodulatory drugs such as teriflunomide, which exerts an inhibitory effect on T-cell activation, and outcome in QuantiFERON results changing from positive to negative with marked reduction in IFN-γ.

These shortcomings may affect the accuracy and scope of testing, which in turn poses challenges to the Latent Tuberculosis Infection (LTBI) Testing industry.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

Qiagen is one of the major players operating in the Latent Tuberculosis Infection (LTBI) Testing market, holding a share of 18.37% in 2021.

QIAGEN is a worldwide provider of molecular sample and assay technologies. Sample technologies are used to collect samples of tissue, fluids, etc. and stabilize, extract and purify various molecules of interest such as DNA, RNA or proteins from other cellular components.

JHP Pharmaceuticals, located in Parsippany, New Jersey, is an integrated specialty healthcare company that specializes in sterile injectable products. JHP manufactures and sells brand aseptic injectable pharmaceuticals in hospital and clinical settings and provides contract manufacturing services for global pharmaceutical companies. JHP's ownproduct portfolio includes leading diagnostic, women's health and anesthesia products.

Segmentation Overview:

Among different product types, Tuberculin Skin Test (TST) segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Household Contacts with Pulmonary TB segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Latent Tuberculosis Infection (LTBI) Testing market covered in Chapter 3:

Sanofi Pasteur Limited
LG Chem
Qiagen
Diasorin
Oxford Immunotec
SD Biosensor
JHP Pharmaceuticals, Inc
LIONEX Diagnostics & Therapeutics GmbH

In Chapter 4 and Chapter 14.2, on the basis of types, the Latent Tuberculosis Infection (LTBI) Testing market from 2018 to 2029 is primarily split into:

Tuberculin Skin Test (TST)
Interferon Gamma Released Assay (IGRA)
ELISpot

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Latent Tuberculosis Infection (LTBI) Testing market from 2018 to 2029 covers:

Household Contacts with Pulmonary TB
PLHIV
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)